What is non-invasive prenatal testing by cell-free DNA?
Non-Invasive Prenatal Testing (NIPT) is a screening test to estimate the chance that the unborn baby has Down syndrome or another chromosome condition (trisomy 18, trisomy 13 or an extra or missing sex chromosome). Normally genetic information (DNA) is contained within a cell. When a cell dies it releases its contents into the blood stream and the DNA is broken up into tiny pieces. This DNA is called cell-free DNA (cfDNA).
NIPT is also known as cfDNA screening. NIPT/cfDNA screening detects, reads and counts cfDNA in a pregnant person’s blood stream. Although this cfDNA is not directly from the baby, it is from the placenta and usually represents the genetic profile of the baby.
What are the benefits of NIPT/cfDNA screening?
- Accuracy: NIPT/cfDNA screening is more accurate than conventional screening tests, detecting more than 99% of pregnancies where the baby has Down syndrome (versus 75-90% by other screening methods).
- Timing: The result from NIPT/cfDNA screening is available earlier than other types of prenatal screening. Current SOGC guidelines recommend that NIPT/cfDNA be performed after 10 weeks’ gestation, with results available about 1-2 weeks after that. Having screening results earlier in pregnancy allows expectant parents more time for decision-making and potentially offers them more options.
What are the limitations of NIPT/cfDNA screening?
- Screening test: While NIPT/cfDNA screening is an excellent test, it cannot tell for sure whether or not your baby has any of the chromosome conditions mentioned above. It is a screening test that provides a chance assessment (high chance or low chance). If the result comes back as high chance for one of the conditions, a diagnostic test such as amniocentesis or chorionic villus sampling (CVS) is recommended before any final decision is acted upon.
- NIPT/cfDNA screening does not screen for all possible conditions: A negative NIPT/cfDNA screening result does not guarantee a healthy baby. A late first trimester ultrasound at 11 to 14 weeks may be offered, where available. An ultrasound at 18-20 weeks gestation is recommended for all pregnancies, regardless of screening results.
- Possibility of re-draw or no results: About 1-8% (1 to 8 in 100) or less of pregnant persons will need to have their blood drawn a second time because the test fails. About half the time a result will be available after this second try. There are various reasons why a test may fail including technical issues with the sample, or not enough cfDNA from the pregnancy (low fetal fraction). Factors that may result in a low fetal fraction are: too early in the pregnancy, chromosome disorder, obesity.
- Incidental findings: NIPT/cfDNA screening also screens for differences in other chromosomes, like the sex chromosomes. Additionally, because this test is also looking at the pregnant person’s cfDNA, occasionally a genetic difference in the pregnant person may be identified.
Who should have NIPT/cfDNA screening?
NIPT/cfDNA screening is available to all pregnant persons and can be used as a second screening test (ie. after receiving a positive First Trimester Screening result or if specific ultrasound differences have been found) or as a first screening test (ie. before any other screening). Ontario Health Insurance Plan (OHIP) will fund NIPT/cfDNA screening for pregnant persons in Ontario who meet certain criteria (see below).
Pregnant persons who do not meet the criteria are able to pay for NIPT/cfDNA screening themselves. Prices vary by company, the average cost being around 500$.
OHIP will fund NIPT/cfDNA screening for pregnant persons who:
– Have a positive prenatal screening result such as First Trimester Screening or other conventional screening methods described in Table 1
– Are over the age of 40 at the expected date of delivery
– Have had a previous pregnancy or child with a chromosome condition
– Have findings on ultrasound which are associated with an increased chance for Down syndrome, trisomy 18 or trisomy 13
There are additional criteria under which a pregnant person is eligible for OHIP-funded NIPT/cfDNA. Requests for funding for these criteria must be ordered by a geneticist or maternal-fetal medicine specialist.
More information about current OHIP-funded NIPT/cfDNA criteria can be found here.
Who offers NIPT/cfDNA screening?
The Ministry of Health and Long Term Care (MOHLTC) has an agreement with two companies to provide NIPT/cfDNA screening in Ontario (Table 2). The technology each company uses to calculate the chance of a chromosome condition is different, but the accuracy of the tests is comparable. If you choose to have NIPT/cfDNA, the company you and your health care provider choose may vary depending on factors listed in Table 2.
Table 2. Non-Invasive Prenatal Testing (NIPT) in Ontario.
Updated July 2018
|HarmonyTM by Ariosa||PanoramaTM by Natera|
|Where is my blood drawn for this test?||DynaCare Next||LifeLabs Genetics|
|How early can I have this test?||10 weeks gestation||9 weeks gestation|
|When would results be available?||10 business days||7-10 calendar days|
|Will this test work if this pregnancy:|
|What proportion of the pregnancies where the baby has Down syndrome will be detected? (Detection rate)||>99%||>99%|
|What proportion of the pregnancies where the baby does not have Down syndrome will be falsely called high risk? (False positive rate)||About 1 in 1,000 (0.1%)||About 1 in 1,000 (0.1%)|
What about the other genetic conditions screened for by NIPT/cfDNA screening?
You may have read that the NIPT/cfDNA screening can suggest other genetic conditions, such as microdeletion and microduplication syndromes. These are rare genetic conditions, occurring in about 1 in 5,000 to 1 in 50,000 pregnancies. They are caused by very tiny extra or missing pieces of chromosomes.
Most of these conditions occur by chance, meaning that they tend to not run in families and can occur out of the blue. The chance of these conditions is not associated with the pregnant person’s age, as it is for Down syndrome and trisomy 18 (conditions caused by extra whole chromosomes).
The addition of these rare conditions to NIPT/cfDNA screening increases the false positive rate. This means that more pregnant persons would receive a positive (high chance) screen result even though the baby does not actually have the condition. This would result in more pregnant persons having diagnostic tests, with associated chance of miscarriage. Current recommendations do not support the routine inclusion of screening for microdeletion and microduplication syndromes in NIPT/cfDNA screening.